Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

4D Molecular Therapeutics, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2021

08/12/2021 | 04:04pm EDT

4D Molecular Therapeutics, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2021. For the quarter, the company reported total revenue of $14,580,000 compared to $3,633,000 a year ago. Loss from operations was $7,596,000 compared to $15,149,000 a year ago. Net loss and comprehensive loss was $7,589,000 compared to $15,153,000 a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.28 compared to $2.92 a year ago. For the six months, the company reported total revenue of $16,580,000 compared to $7,168,000 a year ago. Loss from operations was $23,908,000 compared to $28,426,000 a year ago. Net loss and comprehensive loss was $23,995,000 compared to $28,313,000 a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.90 compared to $5.46 a year ago.


© S&P Capital IQ 2021
All news about 4D MOLECULAR THERAPEUTICS, INC.
10/134D MOLECULAR THERAPEUTICS INC. : Other Events (form 8-K)
AQ
10/114D MOLECULAR THERAPEUTICS' : 4D-125 Drug Shows Potential in Eye Disease Trial
MT
10/104D MOLECULAR THERAPEUTICS : ASRS 2021 Annual Meeting – 4D-125 for XLRP Phase 1/2 Cli..
PU
10/104D MOLECULAR THERAPEUTICS : Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Cli..
AQ
10/104D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Cl..
CI
10/06Health Care Stocks Trade Lower Premarket Wednesday
MT
10/064D MOLECULAR THERAPEUTICS : Obtains FDA Clearance for Phase 1/2 Trial of Wet Age-Related M..
MT
10/064D MOLECULAR THERAPEUTICS : Announces FDA Clearance of IND Application for 4D-710, an A101..
AQ
10/064D MOLECULAR THERAPEUTICS : Announces FDA Clearance of IND Application for 4D-150, a Dual-..
AQ
10/064D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150, a Dual..
CI
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 16,9 M - -
Net income 2021 -71,0 M - -
Net cash 2021 196 M - -
P/E ratio 2021 -12,6x
Yield 2021 -
Capitalization 874 M 874 M -
EV / Sales 2021 40,0x
EV / Sales 2022 256x
Nbr of Employees 104
Free-Float 77,1%
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | FDMT | US35104E1001 | MarketScreener
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 32,39 $
Average target price 50,00 $
Spread / Average Target 54,4%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Melissa Kotterman Vice President-Discovery & Engineering
Fred Kamal Chief Operating & Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-21.86%874
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455